Pulse Biosciences, Inc.

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
14.24 ^USD	+3.56%		+7.31%	-18.21%

Dec. 09	Pulse Biosciences Initiates Research Collaboration for Thyroid Tumors Treatment Using nPulse Technology	MT
Dec. 09	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with Npulse? Technology	CI

Pulse Biosciences Stock Rises; Co-Chairman Duggan May Buy Shares

Published on 11/26/2024 at 02:47 pm EST - Modified on 11/26/2024 at 03:28 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Pulse Biosciences, Inc.

Dec. 09	Pulse Biosciences Initiates Research Collaboration for Thyroid Tumors Treatment Using nPulse Technology	MT
Dec. 09	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with Npulse? Technology	CI
Nov. 21	Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4)	RE
Nov. 24	Pulse Biosciences, Inc., Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Pulse Biosciences Q3 net loss widens	RE
Nov. 05	Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q3 Revenue $86,000	MT
Nov. 05	Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 24	Pulse Biosciences, Inc. Announces First Enrollment in the NANOCLAMP AF Study	CI
Oct. 10	Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system	RE
Oct. 10	Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting	CI
Sep. 17	Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Sep. 16	Pulse Biosciences Insider Sold Shares Worth $1,121,750, According to a Recent SEC Filing	MT
Sep. 15	Pulse Biosciences Insider Bought Shares Worth $2,788,624, According to a Recent SEC Filing	MT
Sep. 08	Pulse Biosciences Announces Fda Ide Approval to Initiate Its Nspfa Cardiac Surgery System Study for the Treatment of Atrial Fibrillation	CI
Sep. 08	Pulse Biosciences Wins FDA Approval to Start Heart Surgery Study	MT
Sep. 08	Pulse Biosciences announces FDA IDE approval to initiate its nsPFA cardiac surgery system study for the treatment of atrial fibrillation	RE
Sep. 02	Pulse Biosciences, Inc. Announces First Successful Procedures in PRECISE Benign Thyroid Nodule Study	CI
Aug. 26	Pulse Biosciences, Inc. Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid	CI
Sep. 03	Pulse Biosciences, Inc., Q2 2025 Earnings Call, Aug 12, 2025
Aug. 12	Pulse Biosciences Q2 Loss Widens	MT
Aug. 12	Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q2 Revenue $0	MT
Aug. 12	Pulse Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jul. 14	Pulse Biosciences, Inc. Appoints Steven T. Weber as Vice President of Accounting and Global Corporate Controller and Principal Accounting Officer, Effective July 14, 2025	CI
Jul. 07	Oppenheimer Initiates Pulse Biosciences at Outperform With $22 Price Target	MT
May. 27	Pulse Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 05:01 PM

Robert William Duggan is a businessperson who founded Robert W. Duggan & Associates and who has been the head of 9 different companies. Presently, Mr. Duggan is Chairman for Pulse Biosciences, Inc., Executive Chairman & Chief Executive Officer for Summit Therapeutics, Inc., Executive Chairman & Chief Executive Officer at Summit Therapeutics Ltd. (a subsidiary of Summit Therapeutics, Inc.) and Chief Executive Officer of Duggan Investments Inc. Mr. Duggan is also on the board of University of California Santa Barbara Foundation, Santa Barbara Foundation, MuOx Ltd. and Human Longevity, Inc. In his past career Mr. Duggan was President of Robert W. Duggan & Associates, Chairman & Chief Executive Officer of Pharmacyclics LLC, Chairman & Chief Executive Officer for Computer Motion, Inc., Chairman of Metropolis Media, Inc. and Chairman at Communication Machinery Corp.

View full profile

Chart Pulse Biosciences, Inc.

Duration

Period

PLSE: Dynamic Chart

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company